VA
CGON icon

VR Adviser’s CG Oncology CGON Stock Holding History

VR Adviser’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-350,000
Closed -$15.4M – 37
2024
Q1 		$15.4M Buy
+350,000
New +$14.3M 0.73% 31

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser's CGON Position: Q2 2024 in Review

VR Adviser sold out of CG Oncology (CGON) in Q2 2024, closing a stake of 350,000 shares — an estimated $15.4M sold.

VR Adviser first reported a position in CGON in Q1 2024 and held it in 1 quarter. The position peaked at $15.4M in Q1 2024. 111 funds tracked by Wall St. Rank hold CGON as of Q2 2024.

  • VR Adviser reported no remaining CG Oncology position as of Q2 2024 after selling out during the quarter.
  • VR Adviser sold 350,000 CG Oncology shares in Q2 2024, an estimated $15.4M.
  • VR Adviser first reported a position in CG Oncology in Q1 2024 and held it in 1 quarter.
  • VR Adviser's CG Oncology position peaked at $15.4M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held CG Oncology as of Q2 2024.

Based on VR Adviser's 13F filing for Q2 2024, filed 14 Aug 2024.